Insamo
Insamo is transforming drug discovery for challenging diseases through its automated platform that designs, synthesizes, and tests cyclic-peptides at an unprecedented scale. By leveraging trillions of proprietary experimental data points, Insamo sets a new standard for scalable machine learning applications in drug design, positioning itself as a leader in the pharmaceutical innovation space.
Insamo
Insamo is transforming drug discovery for challenging diseases through its automated platform that designs, synthesizes, and tests cyclic-peptides at an unprecedented scale. By leveraging trillions of proprietary experimental data points, Insamo sets a new standard for scalable machine learning applications in drug design, positioning itself as a leader in the pharmaceutical innovation space.
TL;DR
What they do: Automated platform to design, synthesize, and test membrane-permeable, orally available cyclic peptides at scale
Founded / HQ: Founded 2022; Berkeley, California
Stage & funding: Seed (early 2024); ~$12.0M reported total funding
Founders / leadership: Co‑founders Timothy (Tim) Craven (CEO) and Toby Passioura (CSO)
Company Overview
Problem Domain
Drug discovery for challenging diseases using cyclic peptides
Founded
2022
Industry
Biotechnology
Tech Stack
Funding Track Record
12000000
Reported Feb 2024 seed round of $12.0M
Non-equity assistance reported on Apr 2, 2024
Investor Signal
“Axial VC, BEVC, Civilization Ventures, Intel Ignite, MRL Ventures Fund, Playground Global, Sahsen Ventures, venBio Partners”